Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on May 7, 2025

red violet Announces First Quarter 2025 Financial Results
BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended March 31, 2025. “We are extremely pleased to report another …

Astera Labs to Participate in the J.P. Morgan 53rd Annual Global Technology, Media, and Communications Conference
SANTA CLARA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Astera Labs (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced that it will participate in the J.P. Morgan 53rd Annual Global …

Crane NXT Reports First Quarter 2025 Results
Completes Acquisition of De La Rue Authentication, a Global Leader in Security and Authentication Technologies Increases Sales Growth Guidance to 6% to 8% for Full Year 2025; Maintaining Full Year EPS Guidance of $4.00 to $4.30 WALTHAM, Mass., May 07, 2025 …

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

HeartCore to Present at Sidoti Micro-Cap Virtual Conference on May 21, 2025 at 11:30 a.m. ET
NEW YORK and TOKYO, May 07, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, will be virtually presenting and holding one- …

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net …

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment …

Cerence Announces Second Quarter Fiscal 2025 Results; Revenue and Profitability Exceed High End of Guidance
Headlines Revenue of $78M; free cash flow of $13.1M marks fourth consecutive positive quarter Company reiterates full-year guidance for revenue and raises full-year guidance for profitability and cash flow Continued innovation and customer momentum for …

Veeco Reports First Quarter 2025 Financial Results
First Quarter 2025 Highlights: Revenue of $167.3 million, compared with $174.5 million in the same period last year GAAP net income of $11.9 million, or $0.20 per diluted share, compared with $21.9 million, or $0.37 per diluted share in the same period …

Silvaco Reports First Quarter 2025 Financial Results
Achieved gross bookings of $13.7 million and revenue of $14.1 million in the first quarter 2025 Signed 9 new customers in the first quarter 2025 and expanded relationship with existing customers across key markets including AI, Photonics, and IoT Expanded …

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million — Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, …

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights …

Magnite Reports First Quarter 2025 Results
Contribution ex-TAC(1) Grows 12% Year-Over-Year Contribution ex-TAC(1) from CTV Grows 15% Year-Over-Year Adjusted EBITDA(1) Grows 47% Year-Over-Year NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side …

electroCore Announces First Quarter 2025 Financial Results
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000 Company to host a conference call …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …